- Home
- NMM vs VRDN Comparison
NMM vs VRDN Comparison
Compare NMM & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- VRDN
- Stock Information
- Founded
- NMM 2007
- VRDN 2006
- Country
- NMM Greece
- VRDN United States
- Employees
- NMM N/A
- VRDN N/A
- Industry
- NMM Marine Transportation
- VRDN Medical Specialities
- Sector
- NMM Consumer Discretionary
- VRDN Health Care
- Exchange
- NMM Nasdaq
- VRDN Nasdaq
- Market Cap
- NMM 959.8M
- VRDN 1.0B
- IPO Year
- NMM 2007
- VRDN N/A
- Fundamental
- Price
- NMM $39.20
- VRDN $13.92
- Analyst Decision
- NMM Strong Buy
- VRDN Strong Buy
- Analyst Count
- NMM 1
- VRDN 12
- Target Price
- NMM $80.00
- VRDN $38.50
- AVG Volume (30 Days)
- NMM 83.5K
- VRDN 838.2K
- Earning Date
- NMM 05-07-2025
- VRDN 05-06-2025
- Dividend Yield
- NMM 0.51%
- VRDN N/A
- EPS Growth
- NMM N/A
- VRDN N/A
- EPS
- NMM 11.23
- VRDN N/A
- Revenue
- NMM $1,319,623,000.00
- VRDN $302,000.00
- Revenue This Year
- NMM N/A
- VRDN N/A
- Revenue Next Year
- NMM $7.93
- VRDN $21,976.14
- P/E Ratio
- NMM $3.49
- VRDN N/A
- Revenue Growth
- NMM 0.28
- VRDN 4.86
- 52 Week Low
- NMM $28.37
- VRDN $9.90
- 52 Week High
- NMM $65.89
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- NMM 58.59
- VRDN 55.94
- Support Level
- NMM $37.81
- VRDN $13.37
- Resistance Level
- NMM $39.90
- VRDN $14.18
- Average True Range (ATR)
- NMM 1.15
- VRDN 0.67
- MACD
- NMM -0.07
- VRDN 0.14
- Stochastic Oscillator
- NMM 37.77
- VRDN 85.65
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).